Navigation Links
Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/3/2010

SAN DIEGO, Nov. 3, 2010 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the third quarter of 2010.  For the quarter ended September 30, 2010, Orexigen reported a net loss of $14.6 million, or $0.31 per share attributable to common stockholders, as compared to a net loss of $14.4 million, or $0.33 per share attributable to common stockholders, for the third quarter of 2009.  As of September 30, 2010, Orexigen had $8.4 million in cash and cash equivalents and an additional $92.2 million in marketable securities, for a total of $100.6 million.

"We had previously set three major goals for the Contrave® program:  partnership, approval and launch," said Michael Narachi, President and CEO of Orexigen. "In the third quarter, we succeeded in executing a North American partnership agreement with Takeda Pharmaceutical Company Limited, which we believe will further our goal of a strong, focused, U.S. market entry for Contrave, if approved. With a partnership in place our attention continues to be on the regulatory review process for Contrave."

Total operating expenses for the third quarter of 2010 were $14.8 million compared to $14.2 million for third quarter of 2009.  The increase in operating expenses primarily reflects an increase in license fees, stock-based compensation expense and salaries and personnel related costs, offset partly by a reduction in research and development expenses related to the completion of Contrave Phase 3 clinical trials and completion of the Phase 2 clinical trial for Empatic™. Notably, operating expenses in the third quarter included $3.0 million in milestones paid to third parties related to the execution of the Takeda collaboration.

Conference Call Today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time)The Orexigen management team will host a teleconference and webcast to discuss the third quarter 2010 financial results and recent business highlights.  The live call may be accessed by phone by calling (800) 884-5695 (domestic) or (617) 786-2960 (international), participant code 70229939.  The webcast can be accessed live on the investor relations section of the Orexigen web site at http://www.orexigen.com, and will be archived for 14 days following the call.

About Orexigen TherapeuticsOrexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company has filed an NDA with the FDA for its lead investigational product, Contrave®. The U.S. Food and Drug Administration (FDA) has scheduled the Endocrinologic and Metabolic Drugs Advisory Committee meeting on December 7, 2010 and the Prescription Drug User Fee Act (PDUFA) action date has been set for January 31, 2011. The Company's second product, Empatic™, has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at www.orexigen.com.

Forward-Looking StatementsOrexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the anticipated action date for the FDA to complete its review of the Contrave NDA and the potential for, and timing of, approval for Contrave. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: risks inherent in the uncertainty of the FDA approval process and other regulatory requirements; the therapeutic and commercial value of Contrave; reliance on third parties to assist with the development of Contrave and the regulatory submissions related thereto; the potential for adverse safety findings relating to Contrave; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in Orexigen's Quarterly Report on Form 10-Q, which we intend to file with the Securities Exchange Commission this week and will be available from the SEC's website (www.sec.gov) and on our website (www.orexigen.com) under the heading "Investor Relations." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.Orexigen Therapeutics, Inc.(a development stage company)Balance Sheets(In thousands, except share and par value amounts)September 30,December 31,20102009(Unaudited)AssetsCurrent assets:Cash and cash equivalents

$
8,372$
37,658Investment securities, available-for-sale

92,23354,500Prepaid expenses and other current assets

1,8501,529Total current assets

102,45593,687Property and equipment, net

9901,324Restricted cash

8811,290Other assets

299547Total assets

$
4,625$
96,848Liabilities and stockholders' equity Current liabilities:Accounts payable and accrued expenses

$
,885$
9,828Deferred revenue, current portion

3,51788Long-term debt, current portion

3,7416,384Total current liabilities

14,14316,300Deferred revenue, less current portion

47,190971Long-term debt, less current portion

-2,416Other long-term liabilities

4901,258Commitments and contingenciesStockholders’ equity:Preferred stock, $.001 par value, 10,000,000 shares authorized at September 30, 2010 and December 31, 2009; noshares issued and outstanding at  September 30, 2010 and December 31, 2009

--Common stock, $.001 par value, 100,000,000 sharesauthorized at September 30, 2010 and December 31, 2009;47,556,739 and 47,215,479 shares issued and outstanding at September 30, 2010 and December 31, 2009, respectively

4847Additional paid-in capital

350,115342,599Accumulated other comprehensive income (loss)

4(6)Deficit accumulated during the development stage

(307,365)(266,737)Total stockholders’ equity

42,80275,903Total liabilities and stockholders’ equity

$
4,625$
96,848Orexigen Therapeutics, Inc.(a development stage company)Statements of Operations(In thousands, except per share amounts)(Unaudited) Period fromThree Months Ended Nine Months Ended September 12, 2002September 30, September 30, (Inception) to 2010200920102009September 30, 2010Revenues:Collaborative agreement $286$-$286$-$

460License revenue 22226666507Total revenues 3082235266967Operating expenses:Research and development 8,1869,59221,75338,579238,312General and administrative 6,6244,59218,82712,25474,826Total operating expenses 14,81014,18440,58050,833313,138Loss from operations (14,502)(14,162)(40,228)(50,767)(312,171)Other income (expense):Interest income 21471012959,113Interest expense (165)(318)(501)(1,070)(4,307)Total other income (expense) (144)(271)(400)(775)4,806Net loss (14,646)(14,433)(40,628)(51,542)(307,365)Accretion to redemption value of redeemable convertible preferred stock ----(78)Deemed dividend of beneficial conversion for Series C preferred stock----(13,860)Net loss attributable to common stockholders$(14,646)$(14,433)$(40,628)$(51,542)$

(321,303)Net loss per share attributable to common stockholders - basic and diluted $(0.31)$(0.33)$(0.86)$(1.38)Shares used in computing net loss per share attributable to common stockholders – basic and diluted 47,44043,08747,29537,484
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
2. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
3. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
4. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
5. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
6. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
7. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
8. Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders
9. Talecris Biotherapeutics Launches PROLASTIN®-C in Canada
10. Cell Therapeutics Awarded $977,917 in Grants Under the Therapeutic Discovery Tax Credit Program
11. Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... , May 2, 2016  While nearly three-quarters of ... can have on their health, only about half report ... to the results of a new survey announced today ... the start of National Osteoporosis Month, Hologic is raising ... affects nearly 56 million Americans. Osteoporosis is ...
(Date:5/2/2016)... SAN FRANCISCO , May 2, 2016 /PRNewswire/ ...  is expected to reach USD 11.1 billion by ... Grand View Research, Inc. Major drivers of the ... in therapeutic areas and government recommendations for periodic ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) ...
(Date:4/29/2016)... , April 29, 2016 ... Review, H1 2016" market research report that provides ... with comparative analysis at various stages, therapeutics assessment ... of administration (RoA) and molecule type, along with ... It also reviews key players involved in the ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... 02, 2016 , ... The National Resident Matching Program® (NRMP®) ... (“the Match”), the system through which U.S. and international medical school students and ... were placed in the 2016 Match, and 29,572 were filled when the matching ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... Dr. Philip ... his patients with same day treatments. In the past, many necessary dental treatments could ... work, along with multiple anesthetic shots and extra chair time. Not only could this ...
(Date:5/2/2016)... ... May 02, 2016 , ... East Los Angeles dentist , ... can visit Dr. Assili to receive any dental extraction treatment for $40 off the ... June 30, 2016. With the lower price, patients can more easily afford extractions to ...
(Date:5/2/2016)... ... , ... This week Omega Institute, a premier nonprofit educational retreat center in ... Omega is offering a record 370 in-person workshops and new online learning opportunities ... interest in or need for the knowledge and skills we’ve been cultivating for nearly ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... new Specialty Pharmacy Patient Satisfaction Award that will recognize specialty pharmacies for their ... from Zitter Health Insights’ Specialty Pharmacy Patient Satisfaction Survey compiled throughout 2016. Results ...
Breaking Medicine News(10 mins):